NCT00562809View on ClinicalTrials.gov

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

PHASE4CompletedINTERVENTIONAL
Enrollment

1,005

Participants

Timeline

Start Date

July 31, 2003

Study Completion Date

August 31, 2004

Conditions
Hypertension
Interventions
DRUG

IRBESARTAN

150/12.5 mg tablets one or two tablets orally per day

Trial Locations (1)

08807

Sanofi-Aventis, Bridgewater

Sponsors

Lead Sponsor

Sanofi

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sanofi

INDUSTRY

NCT00562809 - The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension | Biotech Hunter | Biotech Hunter